Create a 10-15 slide powerpoint presentation to deliver to other neurology doctors
Create a 10-15 slide powerpoint presentation to deliver to other neurology doctors
Created using ChatSlide
The PREVAIL study investigates the significance of complement blockade in AChR-Ab+ gMG, utilising gefurulimab, a dual-binding C5 nanobody, in a phase 3, double-blind, placebo-controlled design. Results show notable improvements in MG-ADL within one week and QMG by week four, with benefits sustained up to week 26. Future practice implications include translating score changes into functional outcomes for patients, evaluating treatment suitability, and addressing self-injection and adherence...